Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy

用于钌基光敏剂介导的术中光动力治疗的光学表面照射器光剂量测定

• 批准号: 10303270
• 负责人: GAL SHAFIRSTEIN
• 金额: $ 24.01万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-20 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10303270
• 关键词: A549; Ablation; Biodistribution; Biological Assay; Biomedical Engineering; Blood Vessels; Cancerous; Cell Survival; Chest; Clinical Research; Data; Devices; Diffuse; Disease; Dose; Dose-Rate; Drug usage; Effectiveness; FDA approved; Face; Fiber; Future; Hand; Hypoxia; Implant; In Vitro; Injections; Lasers; Light; Lung; Magnetic Resonance Imaging; Malignant Neoplasms; Manuals; Measures; Mediating; Movement; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; Operative Surgical Procedures; Optics; Oxygen; Oxygen Consumption; PUVA Photochemotherapy; Patients; Phase; Photosensitivity; Photosensitizing Agents; Pleural; Prediction of Response to Therapy; Production; Prognosis; Rattus; Reaction; Reactive Oxygen Species; Reporting; Ruthenium; Singlet Oxygen; Source; Stat3 protein; Surface; Systemic Therapy; Tail; Testing; Thoracic cavity structure; Time; Tissues; Treatment Efficacy; Tumor Tissue; Variant; Veins; base; cancer cell; crosslink; improved; in vivo; intravenous administration; intravenous injection; light dosimetry; lung cancer cell; non-muscle invasive bladder cancer; novel; novel therapeutics; primary endpoint; response; safety testing; secondary endpoint; standard of care; surgery outcome; tumor

SUMMARY Patients with non-small cell lung cancer (NSCLC) with pleural dissemination face a dire prognosis. Several clinical studies reported that adding intraoperative photodynamic therapy (IO-PDT) to the standard of care surgery prolonged the survival of patients with NSCLC with pleural dissemination. The IO-PDT is accomplished by using a hand-held laser light source to activate a photosensitizer that was administered via intravenous injection 24-48 h prior to treatment. The light delivery is associated with wide variation of light dose rate (irradiance) that can result in inconsistent response to IO-PDT. The intravenous administration of currently used photosensitizers are very sensitive to the variation in light irradiance and are associated with photosensitivity. This proposal aims to improve IO-PDT by: • Using our optical surface applicator (OSA) that precisely controls the irradiance. • Utilizing a safe and potent novel photosensitizer (TLD1433) that can be administered via instillation to reduce photosensitivity during and after surgery and be activated at high irradiance in low oxygen concentrations that will minimize treatment time and be effective in a range of light irradiances. Our overall hypothesis is that the OSA can effectively activate TLD1433 for IO-PDT at high irradiance and low oxygen concentration. To test our hypothesis, we propose to conduct the following aims: Aim 1. To demonstrate that TLD1433-mediated PDT is highly efficient at low oxygen concentration, in vitro, in comparison to the FDA approved photosensitizer (Photofrin®). We will study the in vitro response of lung cancer cells to TLD1433-PDT and Photofrin-PDT at different oxygen concentrations and a range of light irradiance and fluence (dose). The primary endpoint will be cell survival. The secondary endpoint will be the PDT induced photoreaction that will be measured by the degree of the signal transducer and activator of transcription 3 (STAT3) crosslinking, a metric for the photodynamically induced photoreaction via singlet oxygen production. Aim 2. To evaluate the response to TLD1433 mediated IO-PDT with OSA at high irradiance, in vivo, in rats with pleural malignancy. We will use TLD1433-PDT by instillation or Photofrin®-PDT via tail vein injection to treat A549-Luc tumors implanted in lung of experimental rats. The primary endpoint will be PDT induced changes in tumor vascularity that will be evaluated with magnetic resonance imaging (MRI), that could be used as predictive measure for PDT induce ablation and hypoxia. The secondary endpoint will be depth of ablation and hypoxia levels in tumor and normal tissue, ex vivo. These results from this study will be used to guide future studies, where we will test the safety and efficacy of TLD1433 mediated IO-PDT in the treatment of NSCLC, and the use of MRI to predict treatment response via changes in tumor vasculature.

总结